keyword
MENU ▼
Read by QxMD icon Read
search

NAFLD fibrosis score

keyword
https://www.readbyqxmd.com/read/29452268/high-prevalence-of-liver-fibrosis-among-european-adults-with-unknown-liver-disease-a-population-based-study
#1
Llorenç Caballería, Guillem Pera, Ingrid Arteaga, Lluís Rodríguez, Alba Alumà, Rosa Ma Morillas, Napoleón de la Ossa, Alba Díaz, Carmen Expósito, Dolores Miranda, Carmen Sánchez, Rosa Ma Prats, Marta Urquizu, Angels Salgado, Magda Alemany, Alba Martinez, Irfan Majeed, Núria Fabrellas, Isabel Graupera, Ramón Planas, Isabel Ojanguren, Miquel Serra, Pere Torán, Juan Caballería, Pere Ginès
BACKGROUND AND AIMS: Liver fibrosis is the main determinant of long-term outcome in chronic liver diseases. Little is known about prevalence of liver fibrosis in general population. Aim of the study was to investigate the prevalence of liver fibrosis in general adult population with unknown liver disease. METHODS: Population-based, cross-sectional study, performed in Barcelona metropolitan area. Subjects aged 18-75yr were identified randomly from citizens included in primary health care registry...
February 13, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29411270/haptoglobin-genotype-and-vitamin%C3%A2-e-versus-placebo-for-the-treatment-of-nondiabetic-patients-with-nonalcoholic-steatohepatitis-in-china-a-multicenter-randomized-placebo-controlled-trial-design
#2
Shufei Zang, Jin Chen, Yu Song, Lang Bai, Jinjun Chen, Xiaoling Chi, Fangping He, Huiping Sheng, Jing Wang, Shilong Xie, Wen Xie, Yongfeng Yang, Jing Zhang, Minghua Zheng, Zhengsheng Zou, Bingyuan Wang, Junping Shi
INTRODUCTION: Vitamin E is one of the most promising agents for nonalcoholic steatohepatitis (NASH) treatment, and its drug responsiveness may be closely associated with haptoglobin (Hp) genotype. However, its efficacy and safety remain unknown in China. This clinical trial of vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis (VENS) is conducted to evaluate (a) the efficacy and safety of treatment with vitamin E softgel (300 mg/day) determined from standardized histologic scoring of liver biopsies, (b) whether treatment with vitamin E improves biochemical parameters, cytokines, anthropometric parameters, controlled attenuation parameter (CAP), and transient elastography (TE) values determined by Fibroscan and health-related quality of life (SF-36), (c) whether the efficacy of vitamin E treatment is associated with the Hp genotype in nondiabetic adults with NASH...
February 6, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29404500/progression-of-liver-fibrosis-is-associated-with-non-liver-related-mortality-in-patients-with-nonalcoholic-fatty-liver-disease
#3
Toshifumi Tada, Takashi Kumada, Hidenori Toyoda, Kazuyuki Mizuno, Yasuhiro Sone, Tomoyuki Akita, Junko Tanaka
In patients with nonalcoholic fatty liver disease (NAFLD), prognosis and outcome, especially non-liver-related mortality, remain incompletely elucidated. We clarified the mortality from all causes in patients with NAFLD. A total of 4,073 patients with NAFLD diagnosed by ultrasonography were enrolled. We investigated the causes of death and analyzed the mortality from non-liver-related diseases according to the degrees of steatosis and fibrosis using the competing risk method. We used the NAFLD fibrosis score (NFS) to assess fibrosis severity and the ultrasonography fatty liver score to evaluate steatosis severity...
November 2017: Hepatology Communications
https://www.readbyqxmd.com/read/29398327/differing-clinical-phenotype-for-higher-alanine-aminotransferase-alt-compared-with-high-risk-nafld-fibrosis-score-in-type-2-diabetes-mellitus
#4
Kathryn H Williams, Kharis Burns, Stephen M Twigg
AIMS: The impact of non-alcoholic fatty liver disease (NAFLD) presence and severity on the diabetes phenotype remains unclear. Our study aimed to explore and contrast the phenotypes associated with higher ALT and high-risk NAFLD fibrosis score (NFS) in type 2 diabetes. METHODS: 324 patients with type 2 diabetes mellitus who were seen at a diabetes centre for a complications assessment with data for NFS were available for study. Data regarding co-morbidities and pathology were obtained at assessment and by file audit...
December 29, 2017: Journal of Diabetes and its Complications
https://www.readbyqxmd.com/read/29378307/among-patients-with-nonalcoholic-fatty-liver-disease-modest-alcohol-use-is-associated-with-less-improvement-in-histologic-steatosis-and-steatohepatitis
#5
Veeral Ajmera, Patricia Belt, Laura A Wilson, Ryan M Gill, Rohit Loomba, David E Kleiner, Brent A Neuschwander-Tetri, Norah Terrault
BACKGROUND & AIMS: Cross-sectional studies of patients with nonalcoholic fatty liver disease (NAFLD) have reported a lower prevalence of severe disease among modest drinkers compared to non-drinkers. We collected data from adult participants in the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) to evaluate the longitudinal association between modest use of alcohol and histology findings in patients with NAFLD, using paired liver biopsies collected more than 1 year apart...
January 25, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29377462/improvement-of-hepatic-fibrosis-and-patient-reported-outcomes-in-non-alcoholic-steatohepatitis-treated-with-selonsertib
#6
Zobair M Younossi, Maria Stepanova, Eric Lawitz, Michael Charlton, Rohit Loomba, Robert P Myers, G Mani Subramanian, John G McHutchison, Zachary Goodman
BACKGROUND: Patient-reported outcomes (PROs) represent patients' perspective about their well-being. AIM: To assess PRO changes in patients with NASH after treatment with selonsertib (SEL) and to associate them with different biomarkers. METHODS: Patients with NASH and stage 2-3 fibrosis received SEL 6 mg or 18 mg orally QD alone or in combination with simtuzumab (SIM, 125 mg SC weekly) or SIM alone for 24 weeks. Biopsies were obtained at baseline and at treatment week 24...
January 27, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29358469/nonalcoholic-fatty-liver-disease-and-risk-of-incident-type-2-diabetes-a-meta-analysis
#7
REVIEW
Alessandro Mantovani, Christopher D Byrne, Enzo Bonora, Giovanni Targher
OBJECTIVE: Several studies have explored the impact of nonalcoholic fatty liver disease (NAFLD) on risk of incident type 2 diabetes. However, the extent to which NAFLD may confer risk of incident diabetes remains uncertain. We performed a meta-analysis of relevant studies to quantify the magnitude of the association between NAFLD and risk of incident diabetes. RESEARCH DESIGN AND METHODS: We collected data using PubMed, Scopus, and Web of Science from January 2000 to July 2017...
February 2018: Diabetes Care
https://www.readbyqxmd.com/read/29344336/treating-nonalcoholic-fatty-liver-disease-in-patients-with-type-2-diabetes-mellitus-a-review-of-efficacy-and-safety
#8
REVIEW
Elizabeth P Mills, K Paige D Brown, Jennifer D Smith, Phillip W Vang, Katie Trotta
Objective: To review current literature for the efficacy and safety of treatment for nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). Data sources: A PubMed literature search from January 1990 to June 2017 was conducted using the search terms nonalcoholic fatty liver disease, diabetes mellitus, type 2, therapy, treatment, treat, therapeutics, nonalcoholic fatty liver, nonalcoholic hepatosteatosis, NASH, NAFLD, metformin, and statin...
January 2018: Therapeutic Advances in Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29342182/light-alcohol-consumption-has-the-potential-to-suppress-hepatocellular-injury-and-liver-fibrosis-in-non-alcoholic-fatty-liver-disease
#9
Kazutoshi Yamada, Eishiro Mizukoshi, Takuya Seike, Rika Horii, Masaaki Kitahara, Hajime Sunagozaka, Kuniaki Arai, Tatsuya Yamashita, Masao Honda, Shuichi Kaneko
BACKGROUND & AIMS: The modest consumption of alcohol has been reported to decrease the incidence of fatty liver or prevalence of steatohepatitis. In this study, we investigated the effect of light alcohol consumption on liver function and gene expression in patients with non-alcoholic fatty liver disease (NAFLD). METHODS: The study group was formed of 178 patients diagnosed with non-alcoholic fatty liver disease, subclassified into two groups for analysis based on the daily alcohol consumption: non-alcohol group and light alcohol consumer group (≤20 g of ethanol/day)...
2018: PloS One
https://www.readbyqxmd.com/read/29338271/analytical-anthropometric-and-dietary-factors-associated-with-the-development-of-fibrosis-in-patients-with-nonalcoholic-fatty-liver-disease
#10
Sara Gómez de la Cuesta, Rocío Aller de la Fuente, Carla Tafur Sánchez, Olatz Izaola, Concepción García Sánchez, Natalia Mora, Jose Manuel González Hernández, Daniel de Luis Román
BACKGROUND: A prolonged non-alcoholic steatohepatitis (NASH) condition can lead to advanced stages of liver disease and the development of hepatocellular carcinoma. AIM: To evaluate analytical, anthropometric and dietary factors associated with the presence of fibrosis as this is the factor that most influences survival and evolution. METHODS: Seventy-six patients with liver biopsy-diagnosed non-alcoholic fatty liver disease (NAFLD) were included...
January 17, 2018: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/29335916/association-between-obstructive-sleep-apnea-and-non-alcoholic-fatty-liver-disease-a-systematic-review-and-meta-analysis
#11
REVIEW
Shanshan Jin, Suwen Jiang, Airong Hu
The relationship between obstructive sleep apnea (OSA) and non-alcoholic fatty liver disease (NAFLD) has been an issue of great concern. The primary purpose of this study was to determine the influence of OSA on the levels of liver enzymes including alanine transaminase (ALT) and aspartate transaminase (AST). The secondary purpose was to estimate the effect of OSA on the histological lesions of NAFLD, such as steatosis, lobular inflammation, ballooning degeneration, fibrosis, as well as NAFLD activity score (NAS)...
January 15, 2018: Sleep & Breathing, Schlaf & Atmung
https://www.readbyqxmd.com/read/29333610/clinical-features-and-treatment-of-nonalcoholic-fatty-liver-disease-across-the-asia-pacific-region-the-go-asia-initiative
#12
W-K Chan, S Treeprasertsuk, K Imajo, A Nakajima, Y Seki, K Kasama, S Kakizaki, J-G Fan, M J Song, S K Yoon, Y-Y Dan, L Lesmana, K-Y Ho, K-L Goh, V W-S Wong
BACKGROUND: The Gut and Obesity Asia (GO ASIA) workgroup was formed to study the relationships between obesity and gastrointestinal diseases in the Asia Pacific region. AIM: To study factors associated with nonalcoholic steatohepatitis (NASH) and advanced fibrosis, and medical treatment of biopsy-proven nonalcoholic fatty liver disease (NAFLD) patients. METHODS: Retrospective study of biopsy-proven NAFLD patients from centres in the GO ASIA Workgroup...
January 14, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29330836/pathogenesis-of-non-alcoholic-fatty-liver-disease-mediated-by-yap
#13
Ping Chen, Qihui Luo, Chao Huang, Qi Gao, Like Li, Jingfei Chen, Bing Chen, Wentao Liu, Wen Zeng, Zhengli Chen
OBJECTIVE: This study aimed to investigate the mechanism of the interaction between Yes-associated protein (YAP) and transforming growth factor-β (TGF-β)/Smad signaling pathways in the development of non-alcoholic fatty liver disease (NAFLD). METHODS: Serum samples of monkeys with biopsy-proven NAFLD and healthy normal monkeys were used to measure fasting plasma glucose (FPG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride (TG) and albumin (ALB) with the BECKMAN CX5 PRO...
January 12, 2018: Hepatology International
https://www.readbyqxmd.com/read/29318450/the-utility-of-noninvasive-scores-in-assessing-the-prevalence-of-nonalcoholic-fatty-liver-disease-and-advanced-fibrosis-in-type-1-diabetic-patients
#14
Amandeep Singh, Phuc Le, Rocio Lopez, Naim Alkhouri
GOALS: The aim of our study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) and advanced hepatic fibrosis in patients with type 1 diabetes (T1D) using simple noninvasive scores. BACKGROUND: There is paucity of data on the prevalence of NAFLD in T1D. Moreover, T1D could be a risk factor for advanced disease in NAFLD patients. STUDY: Using ICD-9 codes, all patients with the diagnosis of T1D were reviewed and a retrospective chart analysis was carried out on 23,314 patients between the ages of 18 and 80...
January 9, 2018: Hepatology International
https://www.readbyqxmd.com/read/29316577/-combination-of-nafld-fibrosis-score-and-liver-stiffness-measurement-for-identification-of-moderate-fibrosis-stages-ii-iii-in-non-alcoholic-fatty-liver-disease
#15
Andreas Drolz, Malte Wehmeyer, Tom Diedrich, Felix Piecha, Julian Schulze Zur Wiesch, Johannes Kluwe
INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) has become one of the most frequent causes of chronic liver disease. Currently, therapeutic options for NAFLD patients are limited, but new pharmacologic agents are being investigated in the course of clinical trials. Because most of these studies are focusing on patients with fibrosis stages II and III (according to Kleiner), non-invasive identification of patients with intermediate fibrosis stages (II and III) is of increasing interest...
January 2018: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/29288403/the-impact-of-non-alcoholic-fatty-liver-disease-fibrosis-score-on-cardiac-prognosis-in-patients-with-chronic-heart-failure
#16
Tetsuya Takahashi, Tetsu Watanabe, Tetsuro Shishido, Ken Watanabe, Takayuki Sugai, Taku Toshima, Daisuke Kinoshita, Miyuki Yokoyama, Harutoshi Tamura, Satoshi Nishiyama, Takanori Arimoto, Hiroki Takahashi, Tamon Yamanaka, Takuya Miyamoto, Isao Kubota
Liver abnormalities have a strong impact on clinical outcomes in patients with heart failure (HF), and are known as cardio-hepatic syndrome. The non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) has been developed to identify liver fibrosis in patients with NAFLD. It remains to be determined whether NFS is associated with cardiovascular prognosis in patients with chronic heart failure (CHF). We calculated NFS in 516 patients with CHF admitted to our hospital. The clinical endpoints were deaths due to progressive HF, myocardial infarction, stroke, and sudden cardiac death, and rehospitalization for worsening HF...
December 29, 2017: Heart and Vessels
https://www.readbyqxmd.com/read/29278765/gd-eob-dtpa-enhanced-t1%C3%AF-imaging-vs-diffusion-metrics-for-assessment-liver-inflammation-and-early-stage-fibrosis-of-nonalcoholic-steatohepatitis-in-rabbits
#17
Yuanliang Xie, Hongfeng Zhang, Chaoling Jin, Xiang Wang, Xiaoqi Wang, Jingting Chen, Yikai Xu
To assess the value of T1ρ,T1ρ on hepatobiliary phase (HBP) and diffusion metrics in staging of Non-alcoholic fatty liver disease (NAFLD) activity scores, inflammation, fibrosis in NASH rabbits model. Non-alcoholic steatohepatitis (NASH) rabbits model was induced by feeding a varied duration of high-fat, high-cholesterol diet. T1ρ,T1ρ (HBP) 20min after administration of Gd-EOB-DTPA, and Intravoxel incoherent motion imaging (IVIM) diffusion-weighted imaging were performed on a 3.0T magnetic resonance (MR) imaging unit...
December 23, 2017: Magnetic Resonance Imaging
https://www.readbyqxmd.com/read/29274406/association-between-nonalcoholic-fatty-liver-disease-and-subclinical-coronary-atherosclerosis-an-observational-cohort-study
#18
Seung Bum Lee, Gyung-Min Park, Jong-Young Lee, Byung Uk Lee, Jae Ho Park, Byung Gyu Kim, Seok Won Jung, In Du Jeong, Sung-Jo Bang, Jung Woo Shin, Neung Hwa Park, Dong Hyun Yang, Joon-Won Kang, Tae-Hwan Lim, Hong-Kyu Kim, Jaewon Choe, Han Chu Lee
BACKGROUND & AIMS: There are limited data on the association between nonalcoholic fatty liver disease (NAFLD) and subclinical coronary atherosclerosis. This study investigated the influence of NAFLD on subclinical coronary atherosclerosis as detected by coronary computed tomographic angiography (CCTA) in an asymptomatic population. METHODS: A total of 5,121 consecutive asymptomatic individuals with no prior history of coronary artery disease or significant alcohol intake voluntarily underwent abdominal ultrasonography and CCTA as part of a general health examination...
December 20, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29273476/gasdermin-d-plays-a-key-role-as-a-pyroptosis-executor-of-non-alcoholic-steatohepatitis-in-humans-and-mice
#19
Bing Xu, Mingzuo Jiang, Yi Chu, Weijie Wang, Di Chen, Xiaowei Li, Zhao Zhang, Di Zhang, Daiming Fan, Yongzhan Nie, Feng Shao, Kaichun Wu, Jie Liang
BACKGROUND & AIMS: Gasdermin D (GSDMD)-executed programmed necrosis is involved in inflammation and controls interleukin (IL)-1β release. However, the role of GSDMD in non-alcoholic steatohepatitis (NASH) remains unclear. We investigated the role of GSDMD in the pathogenesis of steatohepatitis. METHODS: Human liver tissues from patients with non-alcoholic fatty liver disease (NAFLD) and control individuals were obtained to evaluate GSDMD expression. Gsdmd knockout (Gsdmd-/-) mice, obese db/db mice and their wild-type (WT) littermates were fed with methionine-choline deficient (MCD) or control diet to induce steatohepatitis...
December 20, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29244873/fatty-acids-in-non-alcoholic-steatohepatitis-focus-on-pentadecanoic-acid
#20
Wonbeak Yoo, Donjeta Gjuka, Heather L Stevenson, Xiaoling Song, Hong Shen, Suk Young Yoo, Jing Wang, Michael Fallon, George N Ioannou, Stephen A Harrison, Laura Beretta
Non-alcoholic fatty liver disease (NAFLD) is the most common form of liver disease and ranges from isolated steatosis to NASH. To determine whether circulating fatty acids could serve as diagnostic markers of NAFLD severity and whether specific fatty acids could contribute to the pathogenesis of NASH, we analyzed two independent NAFLD patient cohorts and used the methionine- and choline-deficient diet (MCD) NASH mouse model. We identified six fatty acids that could serve as non-invasive markers of NASH in patients with NAFLD...
2017: PloS One
keyword
keyword
112750
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"